In addition, specific targeting of EGFR ligands (e.g. amphiregulin, heparin-binding EGF-like growth factor) by neutralizing antibodies or small molecules represents a promising therapeutic approach, as it inhibits the proliferation and metastatic events in breast [55] and hepatocellular [56] carcinoma cells. This evidence concerns the gene AREG and carcinoma.